Medela: NICE Recommends Thopaz+ Portable, Digital System for Managing Chest Drains

Food and Healthcare Press Releases Tuesday April 17, 2018 07:25
BAAR, Switzerland--17 Apr--PRNewswire/InfoQuest
  • In multiple clinical trials patients with the Thopaz+ chest drainage system have had shorter chest tube placements and also shorter hospital stays than patients with conventional chest drains.
  • Chest surgery typically requires the insertion of a thin plastic tube into the space between the organs and the chest wall. Chest tubes are painful as the tissues in that area are very sensitive.
  • The NICE resource impact assessment shows that, at a national level, adopting Thopaz+is expected to save around GBP8.5 million per year in England.

The United Kingdom's National Institute for Health and Care Excellence (NICE) has issued a medical technology guidance recommending Thopaz+ (Medela AG Switzerland) for managing chest drains. NICE concluded: "The case for adopting Thopaz+ for managing chest drains is supported by the evidence. Thopaz+ can reduce drainage time and length of stay in hospital, and improves safety for people with chest drains. Its use may also improve clinical decision-making through continuous, objective monitoring of air leaks and fluid loss."

(Photo: https://mma.prnewswire.com/media/676364/Medela_Thopaz_Chest_Drain.jpg )
(Logo: https://mma.prnewswire.com/media/676365/Medela_Logo.jpg )

Chest surgery typically requires the insertion of a thin plastic tube (chest drain) into the space between the organs and the chest wall. Chest tubes are painful as the pleural space and mediastinum are very sensitive sites. Patients require regular pain relief for comfort, and to allow them to complete physiotherapy or mobilisation.

"We are delighted NICE and the Appraisal Committee has reached this decision. The positive conclusion is testament to the value, cost-effectiveness and innovation Thopaz+ brings to the chest drainage paradigm," says Paul Furlong, Managing Director for Medela in the UK.

Thopaz+ is a portable chest drain and digital monitoring system that applies negative pressure as needed and continuously monitors air leakage and fluid drainage. In its internationally recognized independent role to provide evidence-based guidance on health and social care, NICE states that Thopaz+ should especially be considered for people who need chest drainage after pulmonary resection or due to a pneumothorax.

The main benefits behind the use of Thopaz+, as confirmed by NICE's guidance, are a shorter drainage time and a shorter length of stay in hospitals following pulmonary resection. By case, a reduced length of stay in hospital of up to 1.5 days (average 0.4 days) and estimated cost savings of GBP111 per patient per hospital stay were calculated.

"We anticipate that where Thopaz+ is used to manage chest drains there will be a reduced length of stay in hospital. This will allow providers to better utilise beds," concludes the external assessment centre (EAC).

Medela is the leading manufacturer of chest drainage systems in Europe and is pleased by NICE's recognition of the Thopaz+ digital chest drain system.

National Institute for Health and Care Excellence (NICE), an independent organization recognized internationally as a role model for providing evidence-based guidance on health and social care, aims to reduce variation in the availability and quality of NHS treatments and care. NICE is at the vanguard of developing evidence based clinical practice.

Please click   here to read and download the full NICE guideline for the use of Thopaz+.
About Medela

Medela concentrates on two business units: "Human Milk", with basic research recognised globally and leading in the development and manufacture of breastfeeding products and solutions, and "Healthcare", engineering and manufacturing highly innovative medical vacuum technology solutions. In 2007, Medela Healthcare launched the Thopaz cardiothoracic drainage system, followed by the launch of Thopaz+ in 2014.

Media Contact:
anja.zoellner@medela.ch
Burson-Marsteller: daniela.suter@bm.com
+41-444558425
Source: Medela

Latest Press Release

The Menarini Group Announces Meropenem/vaborbactam European Marketing Authorization

- Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections - The first combination of a carbapenem and a beta-lactamase inhibitor approved for clinical use in...

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

- FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of first clinical data in BTC - BTC is a group of rare, aggressive...

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include...

Vitality-linked Insurers to Get 100 million People 20% More Active by 2025

Building on the results of the largest behaviour change study on physical activity, Vitality and its global network of insurers have collectively committed to improving the health of millions over the next seven years. This is in line with the World...

World Congress of Cardiology Cardiovascular Health 2018 Opens in Dubai

- Professor David Wood, President of the World Heart Federation, welcomes more than 5000 cardiologists, doctors, nurses, and health and policy experts from around the world to Dubai for WCC 2018 at a time when the opportunities for a sustainable impact...

Related Topics